CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 130 enrolled
Drug / intervention
PET CTdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04053101
NCT04053101N/ACompleted
CompareCT.gov

Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer

Institut Bergonié·observational·Posted Aug 12, 2019·Updated Sep 18, 2025

In Brief

An observational study evaluating PET CT for Muscle Invasive Bladder Cancer. Completed, enrolled 130 participants across 2 sites.

Detailed Summary

Bladder cancer is the seventh cause of cancer mortality in France. Overall survival is poor, between 45 and 50% at 5 years. Optimal staging of lymph nodes and metastasis is crucial for treatment decision of muscle invasive bladder cancer (MIBC). Guidelines do not recommend FDG-Positron Emission Tomography (PET) Computed Tomography (CT), but rather CT for lymph node and metastatic staging, despite its low accuracy. We performed a retrospective analysis of patients undergoing PET CT for localized MIBC in two centers, to help define the utility of PET CT in this setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMuscle Invasive Bladder Cancer
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 12, 2019
Enrollment StartApr 1, 2017
Primary CompletionDec 31, 2018
Study CompletionAug 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.9 years ago

Interventions

PET CTdevice

Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).